Anti‑lung cancer effect of glucosamine by suppressing the phosphorylation of FOXO

Yu,Zhanwu; Ju,Yinghua; Liu,Hongxu

doi:10.3892/mmr.2017.6976

Anti‑lung cancer effect of glucosamine by suppressing the phosphorylation of FOXO

Authors:
- Zhanwu Yu
- Yinghua Ju
- Hongxu Liu
View Affiliations

Affiliations: Department of Thoracic Surgery, First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: July 14, 2017 https://doi.org/10.3892/mmr.2017.6976
Pages: 3395-3400

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common cause of cancer‑associated mortality worldwide, and glucosamine has the potential to exhibit antitumor activity. To reveal its anti‑lung cancer mechanism, the present study investigated the effect of glucosamine on the transcriptional activity of forkhead box O (FOXO)1 and FOXO3, and associated signal transduction pathways in A549 cells. An MTT assay was performed to investigate cell viability and immunoblotting was performed to detect protein levels of FOXO1/3, phosphorylated (p)‑FOXO1/3, AKT, p‑AKT, extracellular signal‑regulated kinase (ERK) and p‑ERK, and the levels of β‑O‑linked N‑acetylglucosamine (O‑GlcNAc)‑modified FOXO1 protein. Immunoprecipitation was performed to purify O‑GlcNAc‑modified protein prior to immunoblotting. Glucosamine inhibited FOXO1‑ and FOXO3‑specific amino acid phosphorylation, which was correlated with its translocation from the nucleus to cytoplasm, indicating a possible anti‑lung cancer mechanism of glucosamine. The present study also examined the phosphoinositide 3‑kinase (PI3K)/AKT and mitogen‑activated protein kinase (MAPK)/ERK pathways, which induce FOXO1‑ and FOXO3‑specific site phosphorylation. The data showed that glucosamine suppressed the translocation of FOXO from the cytoplasm to the nucleus via glucosamine‑induced O‑GlcNAc modification. These observations suggested that glucosamine modulated A549 cell proliferation, possibly via O‑GlcNAc modification‑induced downregulation of the PI3K/AKT and MAPK/ERK pathways and their downstream signaling molecules, FOXO1 and FOXO3.

View Figures

View References

1	Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
2	Finnberg N and El-Deiry WS: Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: An effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther. 3:614–616. 2004. View Article : Google Scholar : PubMed/NCBI
3	Tran H, Brunet A, Griffith EC and Greenberg ME: The many forks in FOXO's road. Sci STKE. 2003:RE52003.PubMed/NCBI
4	Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L and Coffer PJ: Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol. 20:9138–9148. 2000. View Article : Google Scholar : PubMed/NCBI
5	Schmidt M, de Fernandez Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM and Medema RH: Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol. 22:7842–7852. 2002. View Article : Google Scholar : PubMed/NCBI
6	Yang JY, Xia W and Hu MC: Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol. 29:643–648. 2006.PubMed/NCBI
7	Maiese K, Chong ZZ, Shang YC and Hou J: Clever cancer strategies with FoxO transcription factors. Cell Cycle. 7:3829–3839. 2008. View Article : Google Scholar : PubMed/NCBI
8	Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 117:225–237. 2004. View Article : Google Scholar : PubMed/NCBI
9	Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, et al: ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 10:138–148. 2008. View Article : Google Scholar : PubMed/NCBI
10	de Keizer PL, Packer LM, Szypowska AA, Riedl-Polderman PE, van den Broek NJ, de Bruin A, Dansen TB, Marais R, Brenkman AB and Burgering BM: Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21^cip1-dependent senescence. Cancer Res. 70:8526–8536. 2010. View Article : Google Scholar : PubMed/NCBI
11	Huang H and Tindall DJ: Dynamic FoxO transcription factors. J Cell Sci. 120:2479–2487. 2007. View Article : Google Scholar : PubMed/NCBI
12	Yang JY and Hung MC: A new fork for clinical application: Targeting forkhead transcription factors in cancer. Clin Cancer Res. 15:752–757. 2009. View Article : Google Scholar : PubMed/NCBI
13	Vogt PK, Jiang H and Aoki M: Triple layer control: Phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle. 4:908–913. 2005. View Article : Google Scholar : PubMed/NCBI
14	Rena G, Prescott AR, Guo S, Cohen P and Unterman TG: Rols of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14–3-3 binding, transactivation and nuclear targeting. Biochem J. 354:605–612. 2001. View Article : Google Scholar : PubMed/NCBI
15	Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD and Wistuba II: Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. Cancer Res. 76:675–685. 2016. View Article : Google Scholar : PubMed/NCBI
16	Crolle G and D'Este E: Glucosamine sulphate for the management of arthrosis: A controlled clinical investigation. Curr Med Res Opin. 7:104–109. 1980. View Article : Google Scholar : PubMed/NCBI
17	Meininger CJ, Kelly KA, Li H, Haynes TE and Wu G: Glucosamine inhibits inducible nitric oxide synthesis. Biochem Biophys Res Commun. 279:234–239. 2000. View Article : Google Scholar : PubMed/NCBI
18	Hua J, Sakamoto K and Nagaoka I: Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol. 71:632–640. 2002.PubMed/NCBI
19	Ju Y, Hua J, Sakamoto K, Ogawa H and Nagaoka I: Glucosamine, a naturally occurring amino monosaccharide modulates LL-37-induced endothelial cell activation. Int J Mol Med. 22:657–662. 2008.PubMed/NCBI
20	Ju Y, Hua J, Sakamoto K, Ogawa H and Nagaoka I: Modulation of TNF-α-induced endothelial cell activation by glucosamine, a naturally occurring amino monosaccharide. Int J Mol Med. 22:809–815. 2008.PubMed/NCBI
21	Dalirfardouei R, Karimi G and Jamialahmadi K: Molecular mechanisms and biomedical applications of glucosamine as a potential multifunctional therapeutic agent. Life Sci. 152:21–29. 2016. View Article : Google Scholar : PubMed/NCBI
22	Brasky TM, Lampe JW, Slatore CG and White E: Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control. 22:1333–1342. 2011. View Article : Google Scholar : PubMed/NCBI
23	Hwang MS and Baek WK: Glucosamine induces autophagic cell death through the stimulation of ER stress in human glioma cancer cells. Biochem Biophys Res Commun. 399:111–116. 2010. View Article : Google Scholar : PubMed/NCBI
24	Wang Z, Liang R, Huang GS, Piao Y, Zhang YQ, Wang AQ, Dong BX, Feng JL, Yang GR and Guo Y: Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL. Apoptosis. 11:1851–1860. 2006. View Article : Google Scholar : PubMed/NCBI
25	Oh HJ, Lee JS, Song DK, Shin DH, Jang BC, Suh SI, Park JW, Suh MH and Baek WK: D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K. Biochem Biophis Res Commun. 360:840–845. 2007. View Article : Google Scholar
26	Liu BQ, Meng X, Li C, Gao YY, Li N, Niu XF, Guan Y and Wang HQ: Glucosamine induces cell death via proteasome inhibition in human ALVA41 prostate cancer cell. Exp Mol Med. 43:487–493. 2011. View Article : Google Scholar : PubMed/NCBI
27	Ju Y, Yu A, Sun X, Wu D and Zhang H: Glucosamine, a naturally occurring amino monosaccharide, inhibits A549 and H446 cell proliferation by blocking G1/S transition. Mol Med Rep. 8:794–798. 2013.PubMed/NCBI
28	Ozcan S, Andrali SS and Cantrell JE: Modulation of transcription factor function by O-GlcNAc modification. Biochim Biophys Acta. 1799:353–364. 2010. View Article : Google Scholar : PubMed/NCBI
29	Zheng Y, Jaklitsch MT and Bueno R: Neoadjuvant therapy in non-small cell lung cancer. Surg Oncol Clin N Am. 25:567–584. 2016. View Article : Google Scholar : PubMed/NCBI